261 related articles for article (PubMed ID: 21970835)
1. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors.
Sepúlveda-Méndez J; de Murphy CA; Pedraza-López M; Murphy-Stack E; Rojas-Bautista JC; González-Treviño O
Nucl Med Commun; 2012 Jan; 33(1):69-79. PubMed ID: 21970835
[TBL] [Abstract][Full Text] [Related]
2. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
[TBL] [Abstract][Full Text] [Related]
4. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
5. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
[TBL] [Abstract][Full Text] [Related]
6. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384
[TBL] [Abstract][Full Text] [Related]
7. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
8. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
10. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.
Artiko V; Sobic-Saranovic D; Pavlovic S; Petrovic M; Zuvela M; Antic A; Matic S; Odalovic S; Petrovic N; Milovanovic A; Obradovic V
J BUON; 2012; 17(3):537-42. PubMed ID: 23033296
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
13. The utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for assessment of lung lesions in patients with neuroendocrine tumors.
Pavlovic S; Artiko V; Sobic-Saranovic D; Damjanovic S; Popovic B; Jakovic R; Petrasinovic Z; Jaksic E; Todorovic-Tirnanic M; Saranovic D; Micev M; Novosel S; Nikolic N; Obradovic V
Neoplasma; 2010; 57(1):68-73. PubMed ID: 19895175
[TBL] [Abstract][Full Text] [Related]
14. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
Gómez M; Ferrando R; Vilar J; Hitateguy R; López B; Moreira E; Kapitán M; De Lima F; Agüero B; Gabriela Villegas M; Urdaneta N; Gutiérrez E; Battegazzore A; Bayardo K; Silveira A; Lago G; Páez A
Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
16. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
17. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
19. Kit for preparation of multimeric receptor-specific ⁹⁹mTc-radiopharmaceuticals based on gold nanoparticles.
Ocampo-García B; Ferro-Flores G; Morales-Avila E; Ramírez Fde M
Nucl Med Commun; 2011 Nov; 32(11):1095-104. PubMed ID: 21860334
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
